217 related articles for article (PubMed ID: 32107625)
21. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
22. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
23. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
[TBL] [Abstract][Full Text] [Related]
24. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
[TBL] [Abstract][Full Text] [Related]
25. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
26. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study.
Malagari K; Pomoni M; Moschouris H; Kelekis A; Charokopakis A; Bouma E; Spyridopoulos T; Chatziioannou A; Sotirchos V; Karampelas T; Tamvakopoulos C; Filippiadis D; Karagiannis E; Marinis A; Koskinas J; Kelekis DA
Cardiovasc Intervent Radiol; 2014 Feb; 37(1):165-75. PubMed ID: 24263774
[TBL] [Abstract][Full Text] [Related]
27. HAP score as prognostic factor of hepatocellular carcinoma treated with transarterial chemoembolization in a Latin American center.
Liza Baca E; Díaz Ferrer J
Rev Gastroenterol Peru; 2018; 38(2):164-168. PubMed ID: 30118463
[TBL] [Abstract][Full Text] [Related]
28. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
29. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
30. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
31. Idarubicin
Roth GS; Teyssier Y; Abousalihac M; Seigneurin A; Ghelfi J; Sengel C; Decaens T
World J Gastroenterol; 2020 Jan; 26(3):324-334. PubMed ID: 31988592
[TBL] [Abstract][Full Text] [Related]
32. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
33. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.
Biselli M; Andreone P; Gramenzi A; Trevisani F; Cursaro C; Rossi C; Ricca Rosellini S; Cammà C; Lorenzini S; Stefanini GF; Gasbarrini G; Bernardi M
Clin Gastroenterol Hepatol; 2005 Sep; 3(9):918-25. PubMed ID: 16234031
[TBL] [Abstract][Full Text] [Related]
34. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
[TBL] [Abstract][Full Text] [Related]
35. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
36. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
[TBL] [Abstract][Full Text] [Related]
37. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
[TBL] [Abstract][Full Text] [Related]
38. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.
Sacco R; Bertini M; Petruzzi P; Bertoni M; Bargellini I; Bresci G; Federici G; Gambardella L; Metrangolo S; Parisi G; Romano A; Scaramuzzino A; Tumino E; Silvestri A; Altomare E; Vignali C; Capria A
World J Gastroenterol; 2009 Apr; 15(15):1843-8. PubMed ID: 19370781
[TBL] [Abstract][Full Text] [Related]
40. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.
Kadalayil L; Benini R; Pallan L; O'Beirne J; Marelli L; Yu D; Hackshaw A; Fox R; Johnson P; Burroughs AK; Palmer DH; Meyer T
Ann Oncol; 2013 Oct; 24(10):2565-2570. PubMed ID: 23857958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
